Prior Authorization and Utilization Management

Medicare's $50 GLP-1 lane excludes the diagnoses that justify the drug

The Bridge pilot prices by FDA label rather than medical need, routing sicker patients back to Part D copays. KFF's own math assumes three of four eligible people never enroll.